ArticleFrontiers in pharmacology2026
Terminus-specific antibody development and bioanalytical assay validation to quantify active DR10624 in pharmacokinetic studies.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multi-specific drugs play important roles in addressing multi-factorial disease conditions. DR10624 is a first-in-class long acting Fc fusion triple agonist targeting FGF21R, GLP-1R, and GCGR, which has shown promising efficacy in reducing liver fat and triglycerides. Accurate quantification of the intact, pharmacologically active form of DR10624 in serum is essential for reliable pharmacokinetic (PK) characterization. Methods: Rabbit monoclonal antibodies that specifically recognize the N- and C-termini regions of DR10624 were developed and strategically paired for precise quantification. An electrochemiluminescence (ECL) based immunoassay was established and rigorously validated in accordance with regulatory guidelines. Additionally, a preclinical pharmacokinetic study in cynomolgus monkeys was performed to compare drug exposure using different assay formats. Results: Antibody screening successfully identified highly specific rabbit monoclonal antibodies, notably clones 4G7 and 1A12, which selectively bound to the intact N- and C-termini of DR10624 and effectively neutralized its GLP-1/GCG and FGF21 activities, respectively. Furthermore, the preclinical pharmacokinetic study in cynomolgus monkeys revealed a marked discrepancy between total and intact DR10624 exposure, indicating Discussion: The validated dual-monoclonal ECL method provides a robust and specific approach for quantifying intact, bioactive DR10624 in human serum. This assay supports reliable PK assessment in ongoing and future clinical trials, facilitating the continued development of DR10624 for the treatment of MASLD/MASH, severe hypertriglyceridemia (SHTG), and related metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.